Treatment of Giant Cell Tumor of Bone with Pulmonary Metastasis After Denosumab Failure

Giant cell tumor of bone occasionally spreads to the lungs. Pulmonary metastasis occurs in 1–9% of cases and poses a distinct management challenge once first-line systemic therapy is no longer achieving disease control.

Previous Treatment — Failure Condition

This protocol applies when denosumab — administered every 3 months for enlarging lung metastases — has not achieved its goal of halted progression (stable disease). When lung lesions continue to enlarge despite this regimen, a different approach is required.

Next-Step Approach (Partial Overview)

The management strategy at this stage may involve a surgical intervention targeting the lung lesions in specific circumstances, or, for patients who are not surgical candidates or who decline surgery, an alternative therapy — the full decision algorithm and all applicable options are in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/curroncol31040157

Pulmonary metastasis occurs in 1–9% of cases.

Metastasectomy is performed in the case of complications related to treatment with denosumab.

In patients with inoperable disease or refusal of surgery, denosumab therapy should be re-initiated or stereotactic body radiation therapy should be performed.

View source ↗